Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080407 | 0.77 | — | — | |
| SCHEMBL6197997 | 0.76 | CDK2 (0.50) | CDK2 | |
| SCHEMBL24867729 | 0.69 | CDK2 (0.33) | CDK2 | |
| SCHEMBL3467443 | 0.68 | CDK2 (0.31) | CDK2 | |
| SCHEMBL19521626 | 0.63 | CDK2 (0.31) | CDK2 | |
| SCHEMBL5789370 | 0.63 | — | — | |
| SCHEMBL17801609 | 0.62 | CDK2 (0.34) | CDK2 | |
| SCHEMBL2616422 | 0.60 | CDK2 (0.35) | CDK2 | |
| SCHEMBL2619433 | 0.60 | PIK3CG (0.41) | CDK2 | |
| SCHEMBL14112956 | 0.58 | CDK2 (0.34) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534531-B2 | Thiazole derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-18 | — | — | US | disclosed |
| EP-1282419-A2 | METHODS FOR PREVENTING AND TREATING ALOPECIA INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-12 | — | — | EP | disclosed |
| US-20020061915-A1 | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-23 | — | — | US | disclosed |
| WO-2001080813-A2 | METHODS FOR PREVENTING AND TREATING ALOPECIA INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061915-A1 | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy | NR5A1, CYP17A1, CYP21A2 | CDK2 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.